title: [Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin's lymphoma. Report of the Polish Paediatric LeuKaemia/Lymphoma Study Group].
abstract: The aim of the study was to determine the side effects of asparaginase administration during treatment protocol for childhood non-Hodgkin's lymphoma (NHL). Drug adverse reactions occurred in 20/66 of patients (30,3%) treated in 9 centres in Poland between 1993 and 1998. The most common side effects were coagulation disturbances in 12/66 of the children (18,2%), which occurred due to reduced production of important coagulation factors. Six patients (9,1%) developed impairment of liver function (9,1%). Drug toxicity caused the modifications of treatment protocol in 12/66 (18,2%) of patients, mainly in the induction phase; 3 children died due to relapse of disease.
authors.affiliation: Klinika Hematologii i Chorob Rozrostowych Dzieci AM we Wrocławiu, ul. Bujwida 44, Poland.
authors.forename: G
authors.initials: G
authors.lastname: Wróbel
authors.forename: G
authors.initials: G
authors.lastname: Dobaczewski
authors.forename: B
authors.initials: B
authors.lastname: Kazanowska
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: H
authors.initials: H
authors.lastname: Bubała
authors.forename: A
authors.initials: A
authors.lastname: Dluzniewska
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: A
authors.initials: A
authors.lastname: Kurylak
authors.forename: L
authors.initials: L
authors.lastname: Maciejka-Kapuscinska
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: B
authors.initials: B
authors.lastname: Sopyło
authors.forename: M J
authors.initials: MJ
authors.lastname: Stefaniak
authors.forename: K
authors.initials: K
authors.lastname: Stefańska
authors.forename: E
authors.initials: E
authors.lastname: Stańczak
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
mesh_terms: D000293:Adolescent; D000707:Anaphylaxis / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D003920:Diabetes Mellitus / Q000139:chemically induced; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D007223:Infant; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced; D011044:Poland; D012189:Retrospective Studies; D012640:Seizures / Q000139:chemically induced; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001215:Asparaginase